Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Thyroid (Late Stage^), 2017-2021

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Name
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 4.1 (4.1, 4.1) N/A 13,884 31.3
Wyoming 6 4.1 (3.4, 4.9) 23 (4, 44) 24 27.8
Wisconsin 6 4.2 (4.0, 4.4) 21 (13, 32) 260 32.2
West Virginia 6 3.5 (3.1, 3.9) 37 (22, 45) 69 21.5
Washington 5 4.1 (3.9, 4.3) 25 (15, 33) 328 33.8
Virginia 6 3.4 (3.2, 3.6) 41 (33, 44) 309 30.0
Vermont 6 4.1 (3.4, 4.9) 26 (5, 44) 28 31.5
Utah 3 5.2 (4.9, 5.6) 4 (1, 12) 158 31.4
Texas 3 3.8 (3.7, 3.9) 31 (26, 36) 1,104 33.3
Tennessee 6 2.8 (2.7, 3.0) 46 (43, 48) 208 26.3
South Dakota 6 5.1 (4.4, 5.8) 7 (1, 27) 42 33.1
South Carolina 6 2.6 (2.4, 2.8) 48 (45, 49) 141 27.0
Rhode Island 6 4.2 (3.7, 4.8) 20 (6, 40) 49 27.7
Puerto Rico 6 4.5 (4.1, 4.8) N/A 139 18.6
Pennsylvania 6 4.4 (4.2, 4.5) 18 (11, 24) 607 27.1
Oregon 6 4.4 (4.1, 4.7) 16 (9, 30) 199 36.0
Oklahoma 6 3.4 (3.1, 3.6) 42 (32, 45) 134 26.6
Ohio 6 3.7 (3.5, 3.8) 35 (28, 40) 457 25.3
North Dakota 6 4.4 (3.7, 5.1) 17 (3, 41) 34 28.3
North Carolina 6 3.4 (3.3, 3.6) 39 (33, 43) 373 30.6
New York 3 5.7 (5.6, 5.9) 1 (1, 4) 1,214 31.8
New Mexico 3 5.3 (4.8, 5.7) 3 (1, 13) 115 36.2
New Jersey 3 5.1 (4.9, 5.3) 8 (3, 11) 498 30.3
New Hampshire 6 4.1 (3.7, 4.6) 22 (9, 41) 61 30.8
Nevada 6 4.5 (4.2, 4.8) 13 (7, 27) 145 35.3
Nebraska 6 5.1 (4.7, 5.6) 5 (1, 16) 101 32.3
Montana 6 3.8 (3.3, 4.4) 32 (11, 44) 43 27.8
Missouri 6 3.6 (3.3, 3.8) 36 (30, 43) 233 30.9
Mississippi 6 2.2 (2.0, 2.4) 49 (48, 50) 69 25.9
Minnesota 6 4.0 (3.8, 4.3) 27 (16, 35) 237 32.7
Michigan 6 3.4 (3.3, 3.6) 40 (33, 44) 361 30.0
Maryland 6 4.0 (3.8, 4.2) 28 (16, 35) 259 32.4
Maine 6 4.8 (4.2, 5.3) 9 (2, 28) 69 31.4
Louisiana 3 3.1 (2.9, 3.4) 43 (37, 47) 153 23.5
Kentucky 3 3.9 (3.6, 4.2) 30 (18, 37) 184 28.1
Kansas 6 3.8 (3.5, 4.1) 33 (18, 41) 114 26.7
Iowa 3 4.3 (3.9, 4.6) 19 (10, 33) 139 30.8
Illinois 3 4.4 (4.2, 4.6) 15 (11, 24) 595 33.7
Idaho 3 4.6 (4.2, 5.1) 12 (3, 28) 86 36.5
Hawaii 3 4.4 (4.0, 5.0) 14 (5, 34) 72 36.5
Georgia 3 3.0 (2.9, 3.2) 44 (42, 47) 330 26.1
Florida 6 4.0 (3.9, 4.1) 29 (20, 32) 926 31.3
District of Columbia 6 3.0 (2.4, 3.6) 45 (29, 49) 21 31.6
Delaware 6 3.8 (3.2, 4.4) 34 (11, 45) 38 23.0
Connecticut 3 5.6 (5.3, 6.0) 2 (1, 7) 211 33.6
Colorado 6 5.1 (4.9, 5.4) 6 (2, 11) 309 38.6
California 3 4.7 (4.6, 4.8) 11 (7, 15) 1,935 37.7
Arkansas 6 2.8 (2.6, 3.1) 47 (42, 48) 89 25.7
Arizona 6 4.1 (3.9, 4.3) 24 (15, 33) 300 33.2
Alaska 6 3.5 (2.9, 4.1) 38 (15, 48) 26 30.4
Alabama 6 2.0 (1.9, 2.2) 50 (49, 50) 110 22.9
Indiana 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 10/13/2024 10:10 am.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.
1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
3 Source: SEER November 2023 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2023 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2023 submission).

Data for the United States does not include data from Indiana.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top